1174 / 1578
/
DEGRO AG Stereotaxie Project: TOaSST
Register Study of concomitant use of SRT and
targeted drugs
Study design:
After SRT:
• Patient, tumor, treatment characteristics
3 months:
• Acute toxicity
12 months:
• Late toxicity
• OS, LC, DFS
07.09.17
ESTRO SBRT COURSE 2017 - Matthias Guckenberger
45
/
Discontinuation of TKI
Ø
Minimize procedures with risk of discontinuation of
systemic Tx
Disease flare:
rapid disease progression in patients with TKI
resistance after discontinuation of systemic treatment
MSKCC experience on disease flare:
N=61
NSCLC with mEGFR and TKI treatment
Resistance development
TKI discontinuation
N=14 (
23%
) Disease flare: hospitalization or death
Median 8 days (3-21)
Chaft Cancer Res 2011
07.09.17
ESTRO SBRT COURSE 2017 - Matthias Guckenberger
46